Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Neil Bailey, MSc, Tenzin Tsomo, BS, Jennie Szeto, BA, William I Bensinger, MD, Daniel Egan, MD, Livia Hegerova, MD, Raya Mawad, MD, Ami Batchelder, PA, Joanna Fesler, ARNP, Heather Holdread, MS,NP, Sonia Glennie, ARNP, Judson Hall, ARNP, Joey Ferry, ARNP, Megumi Bailey, MSc, David Kane, RN, John M. Pagel, MDPhD, Krish Patel, MD

Blood (2020) 136 (Supplement 1): 34.

https://doi.org/10.1182/blood-2020-141074

Published: 2020

Journal Articles

The Efficacy of Passive Valve Antimicrobial Swab Caps Against Existing Clabsi Prevention Bundle in an Adult Hematology Inpatient Population: A Quality Improvement Initiative

Joseph F. Ferry, Neil Bailey, MSc, Vanessa Dunleavy, ARNP, Joanna Fesler, ARNP, Judson Hall, PA-C, Sonia Glennie, ARNP, William I Bensinger, MD, Raya Mawad, MD, Krish Patel, MD, Daniel Egan, MD, John M. Pagel, MDPhD, Livia Hegerova, MD

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-143299

Published: 2020

Journal Articles

Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study

Farhad Ravandi, MBBS, Asad Bashey, MD PhD, Wendy Stock, MD, James M. Foran, MD, Raya Mawad, MD, Daniel Egan, MD, William Blum, MD, Allen Yang, MD PhD, Alessandro Pastore, MD, Chelsea Johnson, BSN,RN, Shuo Zheng, Musa Yilmaz, MD, Alice S. Mims, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-134746

Published: 2020

Journal Articles

A Single Center Retrospective Study of Real World Relapsed/Refractory DLBCL Patients Eligible for CAR T-Cell Therapy: Patient Characteristics and Outcomes

Neil Bailey, MSc, John M. Pagel, MD PhD, William Bensinger, MD, Livia Hegerova, MD, Raya Mawad, MD, Michael Milder, MD, Jennie Szeto, BA, Ngan Trinh, BS, Tenzin Tsomo, BS, Paul Wisniewski, BS, Clarisse M. Zayas, Krish Patel, MD

Blood (2018) 132 (Supplement 1): 1715.

https://doi.org/10.1182/blood-2018-99-117780

Published: 2018

Journal Articles

Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study

Farhad Ravandi, MD, Asad Bashey, MD PhD, James M. Foran, MD, Wendy Stock, MD, Raya Mawad, MD, William Blum, MD, M. Wayne Saville, MD, Chelsea M. Johnson, BSN, K. Gary J. Vanasse, MD, Thomas Ly, PhD, Hagop M. Kantarjian, MD, Bhavana Bhatnagar, DO, Koichi Takahashi, MD, Alice S. Mims, MD

Blood (2018) 132 (Supplement 1): 763.

https://doi.org/10.1182/blood-2018-99-119786

Published: 2018

Journal Articles

A Phase 2 Study of Actinium-225 ( 225 Ac)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 µci/Kg/Dose

Ehab L. Atallah, MD, Johnnie J. Orozco, MD PhD, Michael Craig, MD, Moshe Yair Levy, MD, Laura E. Finn, MD, Sharif S. Khan, MD, Alexander E. Perl, MD, Jae H. Park, MD, Gail J. Roboz, MD, William Tse, MD, Kebede H. Begna, MD, Raya Mawad, MD, David A. Rizzieri, MD, Mark S. Berger, MD, Joseph G. Jurcic, MD

Blood (2018) 132 (Supplement 1): 1457.

https://doi.org/10.1182/blood-2018-99-111951

Published: 2018

Journal Articles

Anti-CD45 Radioimmunotherapy Followed By Haploidentical Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Leukemia or High-Risk MDS

Blood (2017) 130 (Supplement 1): 2048.

https://doi.org/10.1182/blood.V130.Suppl_1.2048.2048

Published: 2017

Journal Articles

Fludarabine, Cyclophosphamide, Rituximab (FCR) and Vorinostat Followed By Rituximab and Vorinostat Maintenance Therapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) - Final Results of a Phase I/II Study

Mazyar Shadman, MD MPH, Ajay K Gopal, MD, Oliver Press, MD PhD, David G. Maloney, MD PhD, Raya Mawad, MD, Troy Wadsworth, MD, Trevor W. Dennie, MD, Karl Schultheiss, MD, Kiarash Kojouri, MD MPH, Britt E Kammerer, John M. Pagel, MD PhD

Blood (2016) 128 (22): 4396.

https://doi.org/10.1182/blood.V128.22.4396.4396

Published: 2016

Journal Articles

Idarubicin, Cytarabine and Pravastatin As Induction Therapy for Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Mazyar Shadman, MD MPH, Raya Mawad, MD, Carol Dean, MPH, BSN, Kathleen Shannon-Dorcy, RN,PhD, Vicky Sandhu, MD MPH, Paul C. Hendrie, MD PhD, Bart L. Scott, MD, Roland B. Walter, MD PhD MS, Pamela S. Becker, MD PhD, John Pagel, MD PhD, Elihu H. Estey, MD

Blood (2014) 124 (21): 3732.

https://doi.org/10.1182/blood.V124.21.3732.3732

Published: 2014

Journal Articles

A Randomized Phase II Study of Tosedostat in Combination with Either Cytarabine or Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Raya Mawad, MD, Pamela S. Becker, MD PhD, Paul C. Hendrie, MD PhD, Bart L Scott, MD, Brent L. Wood, MD PhD, Carol Dean, MPH, BSN, Vicky Sandhu, MD MPH, H. Joachim Deeg, MD, Roland B. Walter, MD PhD MS, Lixia Wang, PhD, Jack Singer, MD, Elihu H. Estey, MD, John Pagel, MD PhD

Blood (2014) 124 (21): 3690.

https://doi.org/10.1182/blood.V124.21.3690.3690

Published: 2014

Journal Articles

A Phase II Study Of Tosedostat (TST) In Combination With Either Cytarabine Or Decitabine In Newly Diagnosed Older Patients With Acute Myeloid Leukemia (AML) Or High-Risk Myelodysplastic Syndrome (MDS)

Raya Mawad, MD, Pamela S. Becker, MD, PhD, Paul C. Hendrie, MD, PhD, Bart L Scott, MD, Brent L. Wood, MD, PhD, Carol Dean, RN, Ravinder K Sandhu, MD, H. Joachim Deeg, MD, Roland B. Walter, MD, PhD, Frederick R. Appelbaum, MD, Lixia Wang, PhD, Han Myint, MD, Jack Singer, MD, Elihu H. Estey, MD, John M. Pagel, MD, PhD

Blood (2013) 122 (21): 3926.

https://doi.org/10.1182/blood.V122.21.3926.3926

Published: 2013

Journal Articles

A Phase I/II Study Of Fludarabine, Cyclophosphamide, Rituximab and Vorinostat Followed By Rituximab and Vorinostat Maintenance Therapy In Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia (CLL) Or Small Lymphocytic Leukemia (SLL)

Raya Mawad, MD, Ajay K. Gopal, MD, Oliver W. Press, MD, PhD, David G. Maloney, MD, PhD, Stephen H. Petersdorf, MD, Troy Wadsworth, MD, Trevor W. Dennie, MD, Yoshio Inoue, MD, Karl J. Schultheiss, MD, Kiarash Kojouri, MD, MPH, Kelly M. Smith, MD, Britt Kammerer, John M. Pagel, MD, PhD

Blood (2013) 122 (21): 4191.

https://doi.org/10.1182/blood.V122.21.4191.4191

Published: 2013

Journal Articles

131 I-Tositumomab Consolidation Radioimmunotherapy (RIT) In Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Or Small Lymphocytic Lymphoma (SLL) In First Remission

Mazyar Shadman, MD, MPH, Ajay K. Gopal, MD, Pamela S. Becker, MD, PhD, David G. Maloney, MD, PhD, Barbara Pender, Andrei R. Shustov, MD, Raya Mawad, MD, Britt Kammerer, Oliver W. Press, MD, PhD, John M. Pagel, MD, PhD

Blood (2013) 122 (21): 1644.

https://doi.org/10.1182/blood.V122.21.1644.1644

Published: 2013

Journal Articles

Central Nervous System Relapse In Adults With Acute Lymphoblastic Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation

Amir Hamdi, MD, Raya Mawad, MD, Antonio Di Stasi, MD, Roland Bassett, MS, Roberto Ferro, MD, Ron Ram, MD, Gabriela Rondon, MD, Richard E Champlin, MD, Brenda M. Sandmaier, MD, Kristine C. Doney, MD, Merav Bar, MD, Partow Kebriaei, MD

Blood (2013) 122 (21): 3311.

https://doi.org/10.1182/blood.V122.21.3311.3311

Published: 2013

Journal Articles

A Phase II Trial Combining Radiolabeled Anti-CD45 Antibody with Fludarabine and Low-Dose Total Body Irradiation (TBI) Followed by Related or Unrelated Hematopoietic Cell Transplantation for Patients Under Age 50 with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Raya Mawad, MD, Ted A. Gooley, PhD, Joseph G Rajendran, MD, Darrell R. Fisher, PhD, Ajay K. Gopal, MD, H. Joachim Deeg, MD, Andrew Shields, MD, Damian J. Green, MD, David G. Maloney, MD, PhD, Brenda M. Sandmaier, MD, Rainer Storb, MD, Frederick R. Appelbaum, MD, Oliver W. Press, MD, PhD, John M. Pagel, MD, PhD

Blood (2012) 120 (21): 1924.

https://doi.org/10.1182/blood.V120.21.1924.1924

Published: 2012

Journal Articles

Hematopoietic Bone Marrow Transplantation (BMT) for Patients with High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using HLA-Haploidentical Related Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined with Immunosuppression Before and After BMT

Raya Mawad, MD, Paul O'Donnell, MD, PhD, Ted A. Gooley, PhD, Joseph G Rajendran, MD, Darrell R. Fisher, PhD, Ajay K. Gopal, MD, H. Joachim Deeg, MD, Andrew Shields, MD, Damian J. Green, MD, David G. Maloney, MD, PhD, Brenda M. Sandmaier, MD, Rainer Storb, MD, Frederick R. Appelbaum, MD, Oliver W. Press, MD, PhD, John M. Pagel, MD, PhD

Blood (2012) 120 (21): 4164.

https://doi.org/10.1182/blood.V120.21.4164.4164

Published: 2012

Journal Articles

Safety and Efficacy of Bendamustine and Idarubicin in Combination Therapy for Patients Age ≥50 with Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome – Results From a Phase I/II Adaptive Design Study.

Mazyar Shadman, MD, MPH, Jack M. Lionberger, MD, PhD, Raya Mawad, MD, Ravinder K Sandhu, MD, Carol Dean, RN, Kathleen Shannon-Dorcy, RN, Kyle Wathen, PhD, Bart L Scott, MD, MS, Roland B. Walter, MD, PhD, Pamela S. Becker, MD, PhD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD, John M. Pagel, MD, PhD

Blood (2012) 120 (21): 2622.

https://doi.org/10.1182/blood.V120.21.2622.2622

Published: 2012

NARROW

Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

The Efficacy of Passive Valve Antimicrobial Swab Caps Against Existing Clabsi Prevention Bundle in an Adult Hematology Inpatient Population: A Quality Improvement Initiative

Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study

A Single Center Retrospective Study of Real World Relapsed/Refractory DLBCL Patients Eligible for CAR T-Cell Therapy: Patient Characteristics and Outcomes

Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study

A Phase 2 Study of Actinium-225 ( 225 Ac)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 µci/Kg/Dose

Anti-CD45 Radioimmunotherapy Followed By Haploidentical Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Leukemia or High-Risk MDS

Fludarabine, Cyclophosphamide, Rituximab (FCR) and Vorinostat Followed By Rituximab and Vorinostat Maintenance Therapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) - Final Results of a Phase I/II Study

Idarubicin, Cytarabine and Pravastatin As Induction Therapy for Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

A Randomized Phase II Study of Tosedostat in Combination with Either Cytarabine or Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

A Phase II Study Of Tosedostat (TST) In Combination With Either Cytarabine Or Decitabine In Newly Diagnosed Older Patients With Acute Myeloid Leukemia (AML) Or High-Risk Myelodysplastic Syndrome (MDS)

A Phase I/II Study Of Fludarabine, Cyclophosphamide, Rituximab and Vorinostat Followed By Rituximab and Vorinostat Maintenance Therapy In Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia (CLL) Or Small Lymphocytic Leukemia (SLL)

131 I-Tositumomab Consolidation Radioimmunotherapy (RIT) In Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Or Small Lymphocytic Lymphoma (SLL) In First Remission

Central Nervous System Relapse In Adults With Acute Lymphoblastic Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation

A Phase II Trial Combining Radiolabeled Anti-CD45 Antibody with Fludarabine and Low-Dose Total Body Irradiation (TBI) Followed by Related or Unrelated Hematopoietic Cell Transplantation for Patients Under Age 50 with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Safety and Efficacy of Bendamustine and Idarubicin in Combination Therapy for Patients Age ≥50 with Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome – Results From a Phase I/II Adaptive Design Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only